This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: - Nivolumab - Carboplatin - Pemetrexed - Ipilimumab
Name: Carboplatin
Name: Nivolumab
Name: pemetrexed
Name: Ipilimumab
Description: Complete response (CR) or partial response (PR) per RECIST version 1.1
Measure: Objective Response Rate (ORR) Time: 2 yearsDescription: Complete response (CR), partial response (PR), or stable disease (SD) per RECIST version 1.1
Measure: Disease Control Rate (DCR) Time: 2 yearsDescription: Time from initiation of the study drugs to progression or death, whichever occurs first
Measure: Progression Free Survival (PFS) Time: 2 yearsDescription: Time from initiation of the study drugs to date of death due to any cause
Measure: Overall Survival (OS) Time: 2 yearsDescription: Time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first
Measure: Duration Of Response Time: 2 yearsAllocation: Non-Randomized
Parallel Assignment
There are 2 SNPs
- EGFR-mutant NSCLC: EGFR activating gene mutation (e.g., L858R, exon 19 deletion) as well as a T790M mutation per local testing. --- L858R ---
- EGFR-mutant NSCLC: EGFR activating gene mutation (e.g., L858R, exon 19 deletion) as well as a T790M mutation per local testing. --- L858R --- --- T790M ---
- EGFR-mutant NSCLC (cohorts A and C): Participants must have progressed on or after 1 or more third-generation, T790M mutant-selective EGFR-TKI(s). --- T790M ---